DOI: 10.29245/2578-2967/2018/3.1135 View / Download Pdf View Full Text
Wangqian Zhang1, Cun Zhang2*
1,2State Key Laboratory of Cancer Biology, Biotechnology Center, School of Pharmacy, Fourth Military Medical University, Xi’an, China, 710032
Alondra M. Ortiz Ortiz5, Olivia George6, Khalaf Jasim1,2,7, Andre J. Gesquiere1,2,3,4*
1NanoScience Technology Center, University of Central Florida, Orlando, FL 32826, USA
2Department of Chemistry, University of Central Florida, Orlando, FL 32816, USA
3Department of Materials Science and Engineering, University of Central Florida, Orlando, FL 32816, USA
4The College of Optics and Photonics (CREOL), University of Central Florida, Orlando, FL 32816, USA
5Department of Mechanical Engineering, University of Puerto Rico, Mayaguez Campus, Mayaguez 00681-9000, Puerto Rico
6Department of Chemical Engineering, University of Tennessee at Chattanooga, Chattanooga, TN 37403, Tennessee
7Department of Chemistry, University of Tikrit, Tikrit, Salah Al-Din PO Box 42, Iraq
Many types of cancers require elevated levels of Reactive Oxygen Species (ROS) for uncontrolled proliferation. However, this also makes tumor cells more susceptible to ROS induced cell death by additional oxidative stress caused by external stimuli. By selectively targeting cancer cells and tumors that exhibit high levels of ROS with nanotechnology-based materials to trigger further elevation of ROS therapeutic possibilities become available. Specifically, light-activated treatment through Photodynamic Therapy (PDT) has been demonstrated as a feasible approach with Photophryn as the leading FDA approved sensitizer. However, such small molecule sensitizers do still have significant hurdles to overcome, including poor solubility, non-targeted delivery, and low absorption of light. In this mini review, recent advances in the development of Conjugated Polymer Nanoparticles (CP-NPs) solving these issues are discussed, including amplified ROS generation, tumor targeting, theranostic capabilities, and multimodal CP-NPs. We also give an outlook towards further needs in CP-NP development for clinical application.DOI: 10.29245/2578-2967/2018/3.1134 View / Download Pdf View Full Text
Steven S. Coughlin, PhD, MPH1,2*, Valerie Williams, PT, PhD, DPT, OCS3, Nicole Moore, MS, RD, LD1, Deborah Bowen, PhD4, Judith Anglin, PhD, RD, LD, FAND1, Nadine Mansour, MD, MPH1, Gianluca De Leo, PhD, MBA1
1Department of Clinical and Digital Health Sciences, Augusta University, Augusta, GA
2Research Service, Charlie Norwood Veterans Administration Medical Center, Augusta, GA
3Physical Therapy Department, Augusta University, Augusta, GA
4University of Washington School of Medicine, Seattle, WA
Introduction: Several studies have provided important information about health conditions and other challenges faced by women diagnosed with breast cancer and how they can improve their quality of life and reduce their risk of cancer recurrence. Although African American and Hispanic breast cancer patients have a poorer survival than their white counterparts, few studies have compared the experiences of African American, Hispanic, and non-Hispanic white breast cancer survivors.
Objectives: To facilitate collaborative studies on breast cancer survivorship in a multicultural population, including future intervention research on nutrition, and physical activity, and clinical substudies.
Methods: This cohort study consists of a postal survey of up to 1,000 women with a history of a breast cancer diagnosis who reside in Augusta-Richmond County, Georgia, USA, and a repeat survey in 4 to 5 years to obtain longitudinal data. The follow-up survey in 4 to 5 years will allow for longitudinal changes in health to be assessed.
Conclusion: The survey will provide a comprehensive picture of the health of breast cancer survivors, across the lifespan, in a large Southern city. A broad range of health issues will be addressed including physical activity, diet, nutrition, personal and family history of cancer, quality-of-life, psychosocial concerns, and beliefs about cancer recurrence risk reduction through lifestyle changes. Through its longitudinal design, the study will also provide important information about changes in physical and mental health as breast cancer survivors advance in age.DOI: 10.29245/2578-2967/2018/3.1131 View / Download Pdf View Full Text
Samantha Thifani Alrutz Barcelos1*, Adriana Zanoni Dotti2, Juliano Emanuel Herrera3, Leandra Náira Zambelli Ramalho4
1Medical resident in hepatology HCPA
2Gastroenterologist in São Paulo-SP
4Associate Professor of the Pathology Department FMRP-USP
Endocrine tumors of chromaffin cells are most frequent in the gastrointestinal tract. Moreover, they are the ones of best prognosis. Promising results have been recorded for liver transplantations in case of metastatic gastrointestinal neuroendocrine tumors. We exhibit a case report of a patient presenting dyspeptic and carcinoid syndrome, hepatic metastasis diagnosis and primary tumor of the ileum detected through scheduled hepatectomy. Liver transplantation was the chosen therapy given the impossibility of hepatectomy due to hepatic metastatic involvement. Liver transplantation is a healing therapeutic option for patients with gastrointestinal neuroendocrine tumor in case of unresectable hepatic metastases. It assures more than 50% survival within 5 years in case of primary tumors in the small intestine. Survival is longer in case of liver transplantation after primary tumor resection than in usual palliative treatments such as embolization and chemoembolization.
The article points out the importance of the therapeutic management of the neuroendocrine gastrointestinal metastatic tumor, with emphasis on performing liver transplantation as a possible curative treatment.DOI: 10.29245/2578-2967/2018/3.1124 View / Download Pdf View Full Text